| Psoriasis vulgaris
Ilumya vs Duobrii
Side-by-side clinical, coverage, and cost comparison for psoriasis vulgaris.Deep comparison between: Ilumya vs Duobrii with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsDuobrii has a higher rate of injection site reactions vs Ilumya based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Duobrii but not Ilumya, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Ilumya
Duobrii
At A Glance
SC injection
Every 12 weeks
IL-23 antagonist
Topical
Once daily
Corticosteroid/retinoid combination
Indications
- Psoriasis vulgaris
- Psoriasis vulgaris
Dosing
Psoriasis vulgaris 100 mg SC at Weeks 0, 4, and every 12 weeks thereafter.
Psoriasis vulgaris Apply a thin layer once daily to affected areas, rubbing in gently; total dosage should not exceed approximately 50 g per week; avoid application on the face, groin, or axillae; do not use with occlusive dressings unless directed by a physician; discontinue when control is achieved.
Contraindications
- Previous serious hypersensitivity reaction to tildrakizumab-asmn or any excipient
- Pregnancy
Adverse Reactions
Most common (>=1%) Upper respiratory infections, injection site reactions, diarrhea
Serious Hypersensitivity reactions, infections
Most common (>=1%) contact dermatitis, application site pain, folliculitis, skin atrophy, excoriation, rash, skin abrasion, skin exfoliation
Pharmacology
Tildrakizumab is a humanized IgG1/k monoclonal antibody that selectively binds to the p19 subunit of IL-23 and inhibits its interaction with the IL-23 receptor, thereby suppressing the release of proinflammatory cytokines and chemokines.
Combination of halobetasol propionate, a synthetic corticosteroid that modulates cellular signaling, immune function, and inflammation, and tazarotene, a retinoid prodrug converted by esterase hydrolysis to tazarotenic acid, which binds RAR-beta and RAR-gamma receptors to modify gene expression; precise mechanisms in plaque psoriasis are unknown.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Ilumya
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (9/12) · Qty limit (9/12)
Duobrii
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (9/12) · Qty limit (9/12)
UnitedHealthcare
Ilumya
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Duobrii
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (1/8) · Qty limit (1/8)
Humana
Ilumya
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Duobrii
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAssistance Fund: Psoriasis
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Final cost depends on formulary coverage
No savings programs available for Duobrii.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
IlumyaView full Ilumya profile
DuobriiView full Duobrii profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.